ANI Pharmaceuticals (ANIP) Set to Announce Earnings on Monday

ANI Pharmaceuticals (NASDAQ:ANIPGet Rating) is scheduled to be releasing its earnings data before the market opens on Monday, August 8th. Analysts expect ANI Pharmaceuticals to post earnings of $0.12 per share for the quarter. ANI Pharmaceuticals has set its FY 2022 guidance at $1.34-$1.62 EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.

ANI Pharmaceuticals (NASDAQ:ANIPGet Rating) last posted its quarterly earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.22). The company had revenue of $64.48 million during the quarter, compared to analysts’ expectations of $65.50 million. ANI Pharmaceuticals had a positive return on equity of 6.66% and a negative net margin of 27.78%. During the same period in the prior year, the business posted $0.92 EPS. On average, analysts expect ANI Pharmaceuticals to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

ANI Pharmaceuticals Trading Up 0.9 %

NASDAQ ANIP opened at $34.62 on Friday. The company has a fifty day simple moving average of $29.97 and a two-hundred day simple moving average of $32.00. The stock has a market cap of $597.09 million, a P/E ratio of -7.64 and a beta of 1.05. ANI Pharmaceuticals has a 12-month low of $22.31 and a 12-month high of $60.23. The company has a current ratio of 3.79, a quick ratio of 2.74 and a debt-to-equity ratio of 0.89.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, April 27th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $58.50.

Institutional Trading of ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in ANIP. Fuller & Thaler Asset Management Inc. purchased a new position in ANI Pharmaceuticals during the first quarter valued at $1,306,000. Charles Schwab Investment Management Inc. lifted its holdings in ANI Pharmaceuticals by 2.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 29,195 shares of the specialty pharmaceutical company’s stock valued at $821,000 after purchasing an additional 590 shares in the last quarter. Swiss National Bank lifted its holdings in ANI Pharmaceuticals by 7.1% during the first quarter. Swiss National Bank now owns 27,000 shares of the specialty pharmaceutical company’s stock valued at $759,000 after purchasing an additional 1,800 shares in the last quarter. Rhumbline Advisers lifted its holdings in ANI Pharmaceuticals by 4.4% during the first quarter. Rhumbline Advisers now owns 25,916 shares of the specialty pharmaceutical company’s stock valued at $728,000 after purchasing an additional 1,096 shares in the last quarter. Finally, Prudential Financial Inc. lifted its holdings in ANI Pharmaceuticals by 9.7% during the first quarter. Prudential Financial Inc. now owns 17,538 shares of the specialty pharmaceutical company’s stock valued at $493,000 after purchasing an additional 1,550 shares in the last quarter. Institutional investors and hedge funds own 59.66% of the company’s stock.

ANI Pharmaceuticals Company Profile

(Get Rating)

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies.

Featured Stories

Earnings History for ANI Pharmaceuticals (NASDAQ:ANIP)

Want More Great Investing Ideas?

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.